Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)

La diabetes mellitus postrasplante (DMPT) es una complicación que se encuentra de forma frecuente y se sucede al trasplante de órganos. Existen factores predisponentes a esta complicación, son varios y pueden estar presentes en el pretrasplante, peritrasplante o ya en el pos trasplante; dentro de es...

Full description

Autores:: Acosta González, Juan Daniel
Vázquez Jiménez, Lourdes Carolina
Rodríguez Yánez, Tomás
Daza Arnedo, Rodrigo
Ospina Lopera, Stephanie
Rico Fontalvo, Jorge

Tipo de recurso:

Fecha de publicación:: 2024

Institución:: Universidad Simón Bolívar

Repositorio:: Repositorio Digital USB

Idioma:: spa

id	USIMONBOL2_bd08d50ac68179172733c4f79f00988b
oai_identifier_str	oai:bonga.unisimon.edu.co:20.500.12442/15687
network_acronym_str	USIMONBOL2
network_name_str	Repositorio Digital USB
repository_id_str
dc.title.spa.fl_str_mv	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)
dc.title.translated.eng.fl_str_mv	Therapeutic options in patients with post-diabetes mellitus transplant
title	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)
spellingShingle	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt) Diabetes Mellitus Trasplante Inmunosupresión Hiperglucemia Diabetes pos trasplante Transplant Immunosuppression Hyperglycemia Post-transplant diabetes
title_short	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)
title_full	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)
title_fullStr	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)
title_full_unstemmed	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)
title_sort	Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)
dc.creator.fl_str_mv	Acosta González, Juan Daniel Vázquez Jiménez, Lourdes Carolina Rodríguez Yánez, Tomás Daza Arnedo, Rodrigo Ospina Lopera, Stephanie Rico Fontalvo, Jorge
dc.contributor.author.none.fl_str_mv	Acosta González, Juan Daniel Vázquez Jiménez, Lourdes Carolina Rodríguez Yánez, Tomás Daza Arnedo, Rodrigo Ospina Lopera, Stephanie Rico Fontalvo, Jorge
dc.subject.spa.fl_str_mv	Diabetes Mellitus Trasplante Inmunosupresión Hiperglucemia Diabetes pos trasplante
topic	Diabetes Mellitus Trasplante Inmunosupresión Hiperglucemia Diabetes pos trasplante Transplant Immunosuppression Hyperglycemia Post-transplant diabetes
dc.subject.keywords.eng.fl_str_mv	Transplant Immunosuppression Hyperglycemia Post-transplant diabetes
description	La diabetes mellitus postrasplante (DMPT) es una complicación que se encuentra de forma frecuente y se sucede al trasplante de órganos. Existen factores predisponentes a esta complicación, son varios y pueden estar presentes en el pretrasplante, peritrasplante o ya en el pos trasplante; dentro de estos, se resaltan las terapias inmunosupresoras asociadas. La importancia clínica de DMPT radica en su impacto para la enfermedad cardiovascular (ECV) y enfermedad renal crónica (ERC). En el presente artículo hacemos una revisión de las intervenciones tradicionales y las nuevas terapias para el manejo y tratamiento de la DMPT.
publishDate	2024
dc.date.accessioned.none.fl_str_mv	2024-09-23T15:21:12Z
dc.date.available.none.fl_str_mv	2024-09-23T15:21:12Z
dc.date.issued.none.fl_str_mv	2024
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.driver.none.fl_str_mv	info:eu-repo/semantics/article
dc.type.spa.none.fl_str_mv	Artículo científico
dc.identifier.citation.spa.fl_str_mv	Acosta González J, Vázquez Jiménez L, Rodríguez Yánez T, Daza Arnedo R, Ospina Lopera S, Rico Fontalvo J. Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt). An. Fac. Cienc. Méd. (Asunción), Agosto - 2024; 57(2): 82-89 DOI: http://dx.doi.org/10.18004/anales/2024.057.02.82
dc.identifier.issn.none.fl_str_mv	1816-8949
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/20.500.12442/15687
dc.identifier.doi.none.fl_str_mv	http://dx.doi.org/10.18004/anales/2024.057.02.82
dc.identifier.url.none.fl_str_mv	http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S1816-89492024000200082&lng=es&nrm=iso&tlng=es
identifier_str_mv	Acosta González J, Vázquez Jiménez L, Rodríguez Yánez T, Daza Arnedo R, Ospina Lopera S, Rico Fontalvo J. Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt). An. Fac. Cienc. Méd. (Asunción), Agosto - 2024; 57(2): 82-89 DOI: http://dx.doi.org/10.18004/anales/2024.057.02.82 1816-8949
url	https://hdl.handle.net/20.500.12442/15687 http://dx.doi.org/10.18004/anales/2024.057.02.82 http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S1816-89492024000200082&lng=es&nrm=iso&tlng=es
dc.language.iso.none.fl_str_mv	spa
language	spa
dc.rights.eng.fl_str_mv	Attribution-NonCommercial-NoDerivs 3.0 United States
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.none.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.rights.accessrights.none.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivs 3.0 United States http://creativecommons.org/licenses/by-nc-nd/3.0/us/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.none.fl_str_mv	pdf
dc.publisher.spa.fl_str_mv	Universidad Nacional de Asunción. Editorial de la Facultad de Ciencias Médicas EFACIM
institution	Universidad Simón Bolívar
bitstream.url.fl_str_mv	https://bonga.unisimon.edu.co/bitstreams/5900e975-1c81-4169-8e5e-b63830053d59/download https://bonga.unisimon.edu.co/bitstreams/4ed50e01-8615-430e-9b8f-b24c04be5bf5/download https://bonga.unisimon.edu.co/bitstreams/804c6ff7-6a74-4e85-a078-d21ef72281ee/download https://bonga.unisimon.edu.co/bitstreams/a640ac9a-e7b8-41da-9d5b-1feeb69f73f9/download https://bonga.unisimon.edu.co/bitstreams/68b9a494-53f1-4a12-be5b-7cca36cb23e9/download
bitstream.checksum.fl_str_mv	84600159b879367f4c12210bb1344f38 2f656a26de8af8c32aaacd5e2a33538c 733bec43a0bf5ade4d97db708e29b185 475799bd559e97c28913afdde1f5efc2 1bf33e7d8490430b5bd96ec4cf0abdd2
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Digital Universidad Simón Bolívar
repository.mail.fl_str_mv	repositorio.digital@unisimon.edu.co
_version_	1812100462601568256
spelling	Acosta González, Juan Danielfbcdf6b4-59b6-447e-a918-a3e1566707fd-1Vázquez Jiménez, Lourdes Carolina4793e5bb-f5b2-4dab-af82-7c97f78f765a-1Rodríguez Yánez, Tomás7375c35a-2451-4176-bccc-5ba650e40314-1Daza Arnedo, Rodrigo82ba690f-f5de-45bc-bc67-5d2f7ca76c9f-1Ospina Lopera, Stephaniea15593d1-8b45-46d1-9590-d496d0565325-1Rico Fontalvo, Jorgea156782c-eb0d-4540-a7cb-92742ffaee75-12024-09-23T15:21:12Z2024-09-23T15:21:12Z2024Acosta González J, Vázquez Jiménez L, Rodríguez Yánez T, Daza Arnedo R, Ospina Lopera S, Rico Fontalvo J. Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt). An. Fac. Cienc. Méd. (Asunción), Agosto - 2024; 57(2): 82-89 DOI: http://dx.doi.org/10.18004/anales/2024.057.02.821816-8949https://hdl.handle.net/20.500.12442/15687http://dx.doi.org/10.18004/anales/2024.057.02.82http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S1816-89492024000200082&lng=es&nrm=iso&tlng=esLa diabetes mellitus postrasplante (DMPT) es una complicación que se encuentra de forma frecuente y se sucede al trasplante de órganos. Existen factores predisponentes a esta complicación, son varios y pueden estar presentes en el pretrasplante, peritrasplante o ya en el pos trasplante; dentro de estos, se resaltan las terapias inmunosupresoras asociadas. La importancia clínica de DMPT radica en su impacto para la enfermedad cardiovascular (ECV) y enfermedad renal crónica (ERC). En el presente artículo hacemos una revisión de las intervenciones tradicionales y las nuevas terapias para el manejo y tratamiento de la DMPT.Post transplant diabetes mellitus (PTDM) is a frequent complication after organ transplantation. There are several predisposing factors for this complication, which may be present in the pre-transplant, peri-transplant, or already post-transplant; within these, associated immunosuppressive therapies will be highlighted. The clinical importance of DMPT lies in its impact on cardiovascular disease (CVD) and chronic kidney disease (CKD). In this article, we review traditional interventions and new therapies for managing and treating PTDM.pdfspaUniversidad Nacional de Asunción. Editorial de la Facultad de Ciencias Médicas EFACIMAttribution-NonCommercial-NoDerivs 3.0 United Stateshttp://creativecommons.org/licenses/by-nc-nd/3.0/us/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Diabetes MellitusTrasplanteInmunosupresiónHiperglucemiaDiabetes pos trasplanteTransplantImmunosuppressionHyperglycemiaPost-transplant diabetesOpciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)Therapeutic options in patients with post-diabetes mellitus transplantinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Hecking M, Sharif A, Eller K, Jenssen T. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transpl Int. 2021 Jan;34(1):27-48. doi: 10.1111/tri.13783. Epub 2020 Nov 28. PMID: 33135259; PMCID: PMC7839745.Montero N, Oliveras L, Soler MJ, Cruzado JM. Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics. Clin Kidney J. 2021 Jul 10;15(1):5-13. doi: 10.1093/ckj/sfab131. PMID: 35265335; PMCID: PMC8901587.Malik RF, Jia Y, Mansour SG, Reese PP, Hall IE, Alasfar S, Doshi MD, Akalin E, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, Weng FL, Thiessen Philbrook HR, Parikh CR. Post-transplant Diabetes Mellitus in Kidney Transplant Recipients: A Multicenter Study. Kidney360. 2021 Jun 2;2(8):1296-1307. doi: 10.34067/KID.0000862021. PMID: 35369651; PMCID: PMC8676388.Habibnia F, Oliaei F, Shirafkan H, Abbasi Firoozjah M, Rezaei Roshan M, Akbari R. Ten-year incidence of post-transplant Diabetes Mellitus in renal transplant patients. Diab Vasc Dis Res. 2022;19(6):14791641221137352. Doi: 10.1177/14791641221137352.Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. Nat Rev Endocrinol. marzo de 2019;15(3):172-88. doi: 10.1038/s41574-018-0137-7.Rodríguez-Rodríguez AE, Porrini E, Hornum M, Donate-Correa J, Morales-Febles R, Khemlani Ramchand S, et al. Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update. Nephron. 2021;145(4):317-29. doi: 10.1159/000514288.F V, S F, E S, L R, T J, Jm C, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7(6):1506-14. doi: 10.1111/j.1600-6143.2007. 01749.x.Lawendy B, Srinathan S, Kotha S, Gomes C, Misra S, Yu J, et al. Systematic review and meta-analysis of post-transplant diabetes mellitus in liver transplant recipients. Clin Transplant. 2021;35(7): e14340. doi: 10.1111/ctr.14340.Müller MM, Schwaiger E, Kurnikowski A, Haidinger M, Ristl R, Tura A, et al. Glucose Metabolism After Kidney Transplantation: Insulin Release and Sensitivity with Tacrolimus- Versus Belatacept-Based Immunosuppression. Am J Kidney Dis. 2021 ;77(3):462-464. doi: 10.1053/j.ajkd.2020.07.016.Ducloux D, Courivaud C. Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach. J Pers Med. 2022;12(1):116. doi: 10.3390/jpm12010116.Kuningas K, Driscoll J, Mair R, Smith H, Dutton M, Day E, et al. Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients: A Randomized Controlled Trial. Transplantation. 2020 Jul;104(7):1491-1499. doi: 10.1097/TP.0000000000002969.Wilcox J, Waite C, Tomlinson L, Driscoll J, Karim A, Day E, et al. Comparing glycaemic benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR): study protocol for a randomised controlled trial. Trials. 2016;17(1):417. doi: 10.1186/s13063-016-1543-6.Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. octubre de 2020;98(4S): S1-115. doi: 10.1016/j.kint.2020.06.019.de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-90. /doi.org/10.2337/dci22-0027.Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. Diabetes Care. 2018;41(3):547-53. Diabetes Care. doi: 10.2337/dc17-2231.Anderson S, Cotiguala L, Tischer S, Park JM, McMurry K. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients. Ann Pharmacother. 2021;55(4):496-508. doi: 10.1177/1060028020951955.Miyazaki R, Miyagi K. Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases. BMC Nephrol. 2022;23(1):168. 2022;23(1):168. doi: 10.1186/s12882-022-02793-9.Lim LM, Chang JM, Kuo HT. Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes. Biomedicines. 2023;11(2):470. doi: 10.3390/biomedicines11020470.Thiruvengadam S, Hutchison B, Lim W, Bennett K, Daniels G, Cusack N, et al. Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy. Diabetes Metab Syndr. 2019;13(3):1857-63. doi: 10.1016/j. dsx.2019.04.020.Singh P, Taufeeq M, Pesavento TE, Washburn K, Walsh D, Meng S. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study. Diabetes Obes Metab. 2020;22(5):879-84. doi: 10.1111/dom.13964.Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, et al. Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. Int J Mol Sci. 2021;22(9):4824. doi: 10.3390/ijms22094824.Daza-Arnedo R, Rico-Fontalvo JE, Pájaro-Galvis N, Leal-Martínez V, Abuabara-Franco E, Raad-Sarabia M, et al. Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review. Kidney Med. 2021;3(6):1065-73. doi: 10.1016/j.xkme.2021.07.007.Strøm Halden TA, Åsberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2014;29(4):926-33. 2014 doi: 10.1093/ndt/gft536.Rico-Fontalvo J, Daza-Arnedo R, Cardona-Blanco MX, Leal-Martínez V, Abuabara-Franco E, Pajaro-Galvis N, et al. SGLT2 Inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature. J Clin Nephrol. 2020;4(1):044-55. doi: 10.29328/journal.jcn.1001058AlKindi F, Chaaban A, AlHakim M, Hussain Q, Boobes Y. Review of efficacy and short term safety of sodium - glucose cotransporter 2 (SGLT2) inhibitors use in diabetic renal transplant recipients. Transplantation. 2020;104(S3): S384. doi: 10.1097/01. tp.0000700516.51604.6eSridhar VS, Ambinathan JPN, Gillard P, Mathieu C, Cherney DZI, Lytvyn Y, et al. Cardiometabolic and Kidney Protection in Kidney Transplant Recipients with Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. Transplantation. 1 de abril de 2022;106(4):734-48. doi: 10.1097/TP.0000000000003919.Kwon H, Son SH, Kim K, Jeong JH, Hwang EJ, Yoon CS, et al. Sodium/glucose cotransporter 2 inhibitors reduce microalbuminuria in diabetic renal transplant patients. Transplantation. 2020;104(S3): S430–S430. doi: 10.1097/01. tp.0000700792.22109. b0.Lim J-H, Kwon S, Jeon Y, Kim YH, Kwon H, Kim YS, et al. The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation. 2022;106(9): e404–12. doi: 10.1097/TP.0000000000004228.Lin Y, Mok M, Harrison J, Battistella M, Farrell A, Leung M, et al. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review. Transplant Rev. 2023;37(1):100729. doi: 10.1016/j.trre.2022.100729.Rico Fontalvo JE, Vázquez Jiménez LC, Rodríguez Yánez T, Daza Arnedo R, Raad M, Montejo Hernandez JD, et al. Enfermedad renal diabética: puesta al día. Rev An Fac Cienc Médicas. 2022;55(3):86-98. doi.org/10.18004/anales/2022.055.03.86.ORIGINALPDF.pdfPDF.pdfapplication/pdf388624https://bonga.unisimon.edu.co/bitstreams/5900e975-1c81-4169-8e5e-b63830053d59/download84600159b879367f4c12210bb1344f38MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8905https://bonga.unisimon.edu.co/bitstreams/4ed50e01-8615-430e-9b8f-b24c04be5bf5/download2f656a26de8af8c32aaacd5e2a33538cMD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/804c6ff7-6a74-4e85-a078-d21ef72281ee/download733bec43a0bf5ade4d97db708e29b185MD53TEXTPDF.pdf.txtPDF.pdf.txtExtracted texttext/plain31908https://bonga.unisimon.edu.co/bitstreams/a640ac9a-e7b8-41da-9d5b-1feeb69f73f9/download475799bd559e97c28913afdde1f5efc2MD54THUMBNAILPDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5057https://bonga.unisimon.edu.co/bitstreams/68b9a494-53f1-4a12-be5b-7cca36cb23e9/download1bf33e7d8490430b5bd96ec4cf0abdd2MD5520.500.12442/15687oai:bonga.unisimon.edu.co:20.500.12442/156872024-09-24 03:00:47.188http://creativecommons.org/licenses/by-nc-nd/3.0/us/Attribution-NonCommercial-NoDerivs 3.0 United Statesopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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

Opciones terapéuticas en pacientes con diabetes mellitus post trasplante (dmpt)

Publicaciones similares